Glenmark Pharmaceuticals Limited — Updates, 01-04-2025: Press Release

Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP, available in single-dose vials of 750 mg, 1.25 g, and 1.5 g. This product is bioequivalent and therapeutically equivalent to the reference drug from Mylan Laboratories. The Vancomycin market recorded annual sales of approximately $39.3 million according to IQVIA data for the year ending January 2025. Marc Kikuchi, President & Business Head, North America, expressed enthusiasm over this launch, highlighting its contribution to Glenmark's institutional portfolio. This strategic move may enhance Glenmark’s market presence and revenue potential, reflecting a positive outlook for growth in the competitive pharmaceutical landscape. Investors should monitor the company's continuing expansion in the North American market as this aligns with their broader strategic objectives.